A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Trial Profile

A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Inclisiran (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Cerebrovascular disorders; Coronary disorders; Hypercholesterolaemia; Peripheral arterial disorders
  • Focus Registrational; Therapeutic Use
  • Acronyms ORION-10
  • Sponsors The Medicines Company
  • Most Recent Events

    • 08 Mar 2018 According to The Medicines Company media release, more than 1,500 patients randomized in this trial. Data read-out expected in Q3/2019
    • 08 Mar 2018 Status changed from recruiting to active, no longer recruiting, as reported in The Medicines Company media release.
    • 15 Jan 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top